PROM1 and glioblastoma: Although CD133 has been introduced as a cancer stem marker in GBM and a recent meta-analysis has indicated its clinical significance for GBM patients [12], there is no study investigating the significance of CD133 in various aspects of GBM development and the potential impact of CD133 on the oncogenic signaling pathways of GBM.